Enzymes and technology are used in recombinant DNA technology (rDNA technology) to split or combine one or more genes as needed and introduce them into a new organism to produce a new, desired trait. The technology is used in various industries, including agriculture, human medicines, vaccine production, the poultry industry, high-yield farm animals, and forensics. The technology applies several kinds of cells, layers, and mediums. Bacterial and yeast cells are two of the most popular cell types employed in recombinant DNA technology.
The market worth of recombinant DNA technology in 2021 was USD 707.20 billion, and it will be worth USD 1378.76 billion by 2030, growing at a 7.7% CAGR during the forecast period.
Several firms use recombinant DNA technology to produce insulin, Follistim, human growth hormones, monoclonal antibodies, human albumin, vaccines, gene therapy, and other treatments. It’s also used to make genetically modified crops, biofuel, cloned animals, biopesticides, and other things.
The rapid evolution of technology is facilitating the development of new products. The Recombinant DNA Technology Market is also growing due to increased research and development efforts for treating serious illnesses, including cancer, diabetes, and other immunodeficiency disorders. Additionally, the development of gene therapy as a result of recombinant technology improvements has been employed to cure hereditary illnesses. This will support the Global Recombinant DNA Technology Market’s expansion.
A major limitation for business is the time spent producing new items, which also entails a substantial investment in the business. There are occasionally public concerns about using GM products.
In order to treat or cure an illness, a technique called gene therapy is employed to alter or manipulate gene expression. Novartis developed and received FDA approval for ZOLGENSMA, an FDA-approved medication for type 1 spinal muscular atrophy, in October 2021. The creation of gene therapies helps to regulate and prevent disease by increasing or decreasing gene expression. As a result, additional gene therapy research might improve a company’s market opportunity to cure complex disorders.
In 2020, the therapeutic agent segment considerably held the largest position in the market. Therapeutic substances are those that are employed in the management of a condition or illness. The FDA has approved several medicinal substances that are employed to treat a variety of illnesses and disorders. For instance, in 2007, the FDA authorized EPOGEN, erythropoietin alfa, which is used to treat anemia brought on by malignancies and HIV infection.
In 2021, the Health & Diseases segment held the largest position in the market. Human-use medications are primarily produced with the use of this technology. Additionally, there is a rise in the desire to use technology to heal animals. The demand for different medications and vaccinations that enhance consumers’ health will increase in the upcoming years, likely leading to market growth.
In 2021, the market was ruled by the Expression System category. The market is growing significantly as a result of increased Research and Development (R&D) efforts connected to useful protein expression. The full potential of the bacterial, insect and mammalian systems has been employed. The use of plants as an expression system has also been the subject of substantial research in recent years, which supports the segment’s expansion.
In 2021, North America ruled the market for recombinant DNA technology. The US ruled the market in North America because of the presence of various manufacturing facilities. Other important aspects contributing to regional market expansion include the rise in pharmaceutical and biotechnological enterprises and research institutions, increasing investments, and growing public knowledge of the advantages of recombinant DNA technology. Additionally, the rising use of gene therapy will have a beneficial impact on the future growth of the regional industry.
- Novartis AG
- Thermo Fisher Scientific Inc.
- Novo Nordisk
- DuPont Pioneer
The market worth of recombinant DNA technology in 2021 was USD 707.20 billion, and it will be worth USD 1378.76 billion by 2030, growing at a 7.7% CAGR during the forecast period. Massive developments and a broad range of uses for recombinant DNA technology to treat fatal human illnesses like cancer, diabetes, and infectious diseases are the main drivers of market expansion.